SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression

Nature Communications

Volumn 5, Issue , 2014, Pages

  Bellail, Anita C ^a   Olson, Jeffrey J ^b   Hao, Chunhai ^a  

^a MCGILL UNIVERSITY   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; SUMO 1 PROTEIN; CYCLIN DEPENDENT KINASE 1; UBIQUITIN;

BIOCHEMISTRY; CANCER; CYTOLOGY; DEGRADATION; DISEASE TREATMENT; ENZYME ACTIVITY; FUNCTIONAL ROLE; GENE EXPRESSION; PROTEIN; TUMOR;

ARTICLE; CELL CYCLE; CONJUGATION; DISEASE COURSE; G1 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SUMOYLATION; UBIQUITINATION; AMINO ACID SEQUENCE; ANIMAL; BRAIN TUMOR; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BRAIN NEOPLASMS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; GLIOBLASTOMA; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN STABILITY; SUMO-1 PROTEIN; UBIQUITIN; UBIQUITINATION;

EID: 84903125838     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5234     Document Type: Article

References (65)

1. Hay, R. T. SUMO: a history of modification. Mol. Cell 18, 1-12 (2005). (Pubitemid 40444643)
2. Geiss-Friedlander, R. & Melchior, F. Concepts in SUMOylation: a decade on. Nat. Rev. Mol. Cell Biol. 8, 947-956 (2007). (Pubitemid 350176509)
3. Gareau, J. R. & Lima, C. D. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat. Rev. Mol. Cell Biol. 11, 861-871 (2010).
4. Bhoj, V. G. & Chen, Z. J. Ubiquitylation in innate and adaptive immunity. Nature 458, 430-437 (2009).
5. Bernier-Villamor, V., Sampson, D. A., Matunis, M. J. & Lima, C. D. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108, 345-356 (2002). (Pubitemid 34178399)
6. Golebiowski, F. et al. System-wide changes to SUMO modifications in response to heat shock. Sci. Signal. 2, ra24 (2009).
7. Becker, J. et al. Detecting endogenous SUMO targets in mammalian cells and tissues. Nat. Struct. Mol. Biol. 20, 525-531 (2013).
8. Hay, R. T. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 17, 370-376 (2007). (Pubitemid 47375105)
9. Mikolajczyk, J. et al. Small ubiquitin-related modifier (SUMO)-specific proteases: profiling the specificities and activities of human SENPs. J. Biol. Chem. 282, 26217-26224 (2007). (Pubitemid 47443769)
10. Bergink, S. & Jentsch, S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458, 461-467 (2009).
11. Creton, S. & Jentsch, S. SnapShot: the SUMO system. Cell 143, 848-848, e841 (2010).
12. Flotho, A. & Melchior, F. SUMOylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 82, 357-385 (2013).
13. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166 (2009).
14. Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 6, 369-381 (2006).
15. Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566 (2009).
16. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
17. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
18. Bawa-Khalfe, T. & Yeh, E. T. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 1, 748-752 (2010).
19. Kim, J. H. et al. Roles of SUMOylation of a reptin chromatin-remodelling complex in cancer metastasis. Nat. Cell Biol. 8, 631-639 (2006). (Pubitemid 43827357)
20. Kubota, Y., O'Grady, P., Saito, H. & Takekawa, M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat. Cell Biol. 13, 282-291 (2011).
21. Bertolotto, C. et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480, 94-98 (2011).
22. Kessler, J. D. et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348-353 (2012).
23. Reardon, D. A., Rich, J. N., Friedman, H. S. & Bigner, D. D. Recent advances in the treatment of malignant astrocytoma. J. Clin. Oncol. 24, 1253-1265 (2006). (Pubitemid 46622028)
24. Bellail, A. C., Olson, J. J., Yang, X., Chen, Z. J. & Hao, C. A20 ubiquitin ligasemediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2, 140-155 (2012).
25. Wang, C. X. et al. Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2. Cell Death Differ. 13, 1203-1212 (2006). (Pubitemid 43905600)
26. De Brabander, M. J., Van de Veire, R. M., Aerts, F. E., Borgers, M. & Janssen, P. A. The effects of methyl (5-(2-thienylcarbonyl)-1H-benzimidazol-2- yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro. Cancer Res. 36, 905-916 (1976).
27. Vassilev, L. T. et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl Acad. Sci. USA 103, 10660-10665 (2006). (Pubitemid 44078033)
28. Bonne-Andrea, C. et al. SUMO2/3 modification of cyclin E contributes to the control of replication origin firing. Nat. Commun. 4, 1850 (2013).
29. Xu, X. M., Yoo, M. H., Carlson, B. A., Gladyshev, V. N. & Hatfield, D. L. Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression. Nat. Protoc. 4, 1338-1348 (2009).
30. Wiedemeyer, W. R. et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc. Natl Acad. Sci. USA 107, 11501-11506 (2010).
31. Michaud, K. et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70, 3228-3238 (2010).
32. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004). (Pubitemid 39551674)
33. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006). (Pubitemid 44949604)
34. Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403 (2006). (Pubitemid 43668737)
35. Castillo-Lluva, S. et al. SUMOylation of the GTPase Rac1 is required for optimal cell migration. Nat. Cell Biol. 12, 1078-1085 (2010).
36. Sampson, D. A., Wang, M. & Matunis, M. J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 276, 21664-21669 (2001).
37. Rodriguez, M. S., Dargemont, C. & Hay, R. T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654-12659 (2001).
38. Matic, I. et al. Site-specific identification of SUMO-2 targets in cells reveals an inverted SUMOylation motif and a hydrophobic cluster SUMOylation motif. Mol. Cell 39, 641-652 (2010).
39. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. & Jentsch, S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-141 (2002). (Pubitemid 35025438)
40. Desterro, J. M., Rodriguez, M. S. & Hay, R. T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol. Cell 2, 233-239 (1998). (Pubitemid 128373648)
41. Russo, A. A., Tong, L., Lee, J. O., Jeffrey, P. D. & Pavletich, N. P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395, 237-243 (1998). (Pubitemid 28447541)
42. Brotherton, D. H. et al. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 395, 244-250 (1998). (Pubitemid 28447542)
43. Schulze-Gahmen, U. & Kim, S. H. Structural basis for CDK6 activation by a virus-encoded cyclin. Nat. Struct. Biol. 9, 177-181 (2002). (Pubitemid 34171308)
44. Reverter, D. & Lima, C. D. A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex. Structure. 12, 1519-1531 (2004). (Pubitemid 39092096)
45. Holt, L. J. et al. Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. Science 325, 1682-1686 (2009).
46. Su, Y. F., Yang, T., Huang, H., Liu, L. F. & Hwang, J. Phosphorylation of Ubc9 by Cdk1 enhances SUMOylation activity. PLoS ONE 7, e34250 (2012).
47. Seufert, W., Futcher, B. & Jentsch, S. Role of a ubiquitin- conjugating enzyme in degradation of S-and M-phase cyclins. Nature 373, 78-81 (1995).
48. Tatham, M. H. et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538-546 (2008). (Pubitemid 351627373)
49. Rane, S. G. et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet. 22, 44-52 (1999).
50. Ortega, S. et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35, 25-31 (2003). (Pubitemid 37048592)
51. Geng, Y. et al. Cyclin E ablation in the mouse. Cell 114, 431-443 (2003). (Pubitemid 37100992)
52. Malumbres, M. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493-504 (2004). (Pubitemid 39485668)
53. Kozar, K. et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477-491 (2004). (Pubitemid 39485667)
54. Murphy, M. et al. Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat. Genet. 15, 83-86 (1997). (Pubitemid 27014955)
55. Brandeis, M. et al. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc. Natl Acad. Sci. USA 95, 4344-4349 (1998).
56. Santamaria, D. et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811-815 (2007). (Pubitemid 47266342)
57. Yu, Q., Geng, Y. & Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021 (2001). (Pubitemid 32612319)
58. Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23-32 (2006). (Pubitemid 43069508)
59. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010).
60. Sicinska, E. et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461 (2003). (Pubitemid 38050042)
61. Hu, M. G. et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 69, 810-818 (2009).
62. Choi, Y. J. et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438-451 (2012).
63. Sawai, C. M. et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell 22, 452-465 (2012).
64. Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427-1438 (2004).
65. Phelps, D. E. & Xiong, Y. Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6. Methods Enzymol. 283, 194-205 (1997). (Pubitemid 27339781)